By Michele Maatouk
Date: Thursday 10 Oct 2019
(Sharecast News) - Belgian drug maker UCB has agreed to buy US-based clinical-stage biopharmaceuticals company Ra Pharmaceuticals for $2.1bn.
No recent information was found.
GSK gets emerging markets boost with UCB deal | 24-Jan-2009 | Telegraph |
UCB confident on drug go-ahead | 21-Aug-2007 | The Scotsman |
Fellner shuffles Acambis board | 08-Mar-2007 | Telegraph |
Deal speeds drugs sector consolidation | 26-Sep-2006 | The Herald |
No recent information was found.
No recent information was found.
Currency | Euro |
Share Price | 209.80 |
Change Today | 1.40 |
% Change | 0.67 % |
52 Week High | 210.70 |
52 Week Low | 129.35 |
Volume | 111,521 |
Shares Issued | 190.00m |
Market Cap | 39,862m |
Beta | 1.61 |
Strong Buy | 7 |
Buy | 11 |
Neutral | 3 |
Sell | 0 |
Strong Sell | 0 |
Total | 21 |
Time | Volume / Share Price |
17:35 | 388 @ 209.80 |
17:35 | 44 @ 209.80 |
17:35 | 44 @ 209.80 |
17:35 | 598 @ 209.80 |
17:35 | 258 @ 209.80 |
You are here: research